EP Patent

EP3972569A1 — Nanoparticles comprising enzalutamide

Assigned to HELM PHARMACEUTICALS GmbH · Expires 2022-03-30 · 4y expired

What this patent protects

The invention relates to nanoparticles comprising Enzalutamide, processes for the preparation of such nano- particles, pharmaceutical compositions and pharmaceutical dosage forms comprising such nanoparticles, pro- cesses for the preparation of such pharmaceutical dosage forms, a…

USPTO Abstract

The invention relates to nanoparticles comprising Enzalutamide, processes for the preparation of such nano- particles, pharmaceutical compositions and pharmaceutical dosage forms comprising such nanoparticles, pro- cesses for the preparation of such pharmaceutical dosage forms, and uses of the pharmaceutical dosage forms for medical purposes.

Drugs covered by this patent

Patent Metadata

Patent number
EP3972569A1
Jurisdiction
EP
Classification
—
Expires
2022-03-30
Drug substance claim
No
Drug product claim
No
Assignee
HELM PHARMACEUTICALS GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.